The Minister of Public Health, luigi medina ruizmet the research doctor of Siprosa, Conrad Llapurto talk about the research projects currently underway in the province for three different target populations – pediatricians, pregnant women and the elderly – concerning a vaccine that allows the prevention of respiratory syncytial virus.
Bronchiolitis is the disease generated mainly by the respiratory syncytial virus, it affects children under the age of 2 years – especially newborns – obstructing the bronchioles with secretions and inflaming them, which leads to respiratory failure which in many cases leads the infant population to require admissions to intensive care with mechanical respiratory assistance.
The head of the healthcare portfolio underlined the leading role that Tucumán plays in the research that is being carried out worldwide and for which we have been selected: “With more than 600 patients, this vaccination protocol, which is already entered phase 3.
The Minister of Public Health, Dr. Luis Medina Ruiz, met with the medical researcher of Siprosa, Dr. Conrado Llapur, to talk about the research projects currently underway in the province for three different target populations: pediatrics, pregnant women and elderly adults – in terms of a vaccine that allows the prevention of respiratory syncytial virus.
Bronchiolitis is the disease generated mainly by the respiratory syncytial virus, it affects children under the age of 2 years – especially newborns – obstructing the bronchioles with secretions and inflaming them, which leads to respiratory failure which in many cases leads the infant population to require admissions to intensive care with mechanical respiratory assistance.
The head of the healthcare portfolio underlined the leading role that Tucumán plays in the research that is being carried out worldwide and for which we have been selected: “With more than 600 patients, this vaccination protocol, which is already entered phase 3 The formula is inserted into pregnant women in such a way that antibodies are passed on to the newborn, to provide protection against bronchiolitis of more than 82% in the first 90 days of life.
In this sense, Llapur highlighted that the results of the study of a new vaccine against the respiratory syncytial virus that causes bronchiolitis in children have already been seen: “One of the studies that was conducted in Maternity and Mayo Clinic, where women in pregnancy with this immunization, it has been seen that it has a level of protection and efficacy against respiratory diseases due to the syncytial virus of 80 percent up to 3 months of life and about 70 percent at 6 months “, said the Once highlighted against this disease – which has high morbidity and mortality in infants and children under 1 year of age – there is no therapeutic strategy so far beyond an approved antibody for premature infants and which offers oxygen support.
Following this line, the researcher argued that the work is underway in phase 3, of preliminary analyzes and highlighted that, although the study continues, with these we begin to see the effectiveness of the vaccine, which makes it probable that the year thereafter, all related submissions are made for its approval.
Another study also conducted between the public and private health sectors – Avellaneda Hospital and Mayo Clinic – also tests the vaccine against respiratory syncytial virus, but in adults over the age of 60. “This is also a disease that produces symptoms similar to those of influenza or influenza in this population, especially in terms of mortality, morbidity, hospitalizations, and in this case the vaccine was effective close to 85 percent. in the prevention of the disease., therefore it could reduce hospitalizations and severe cases in the elderly, ”he commented.
Llapur also said that the province has also participated – from Niño Jesús hospital and the Mayo Clinic – in studies of a monoclonal antibody for respiratory syncytial virus in children under one year of age, which showed 75% efficacy. : “Today Tucumán, both in the public and private part in terms of research for the prevention of diseases that currently do not have preventive treatments, is working well and results are being produced, for this reason we appreciate the support of the Ministry and the population that participates so that to contribute to science from the province in search of better health for all ”.
For his part, the medical director of the Mayo Clinic, Dr. Víctor Zimmerman, said: “It is a pride for Tucumán and for our center to be able to participate together with the Ministry of Public Health through a union between public and private sectors, in these investigations. . We are very proud of the medical staff who are working within these projects with the results that are displayed and we should work even more together, because the patients are the same “, the professional reflected, adding that the work is constantly monitored by them. vaccine manufacturers, which requires compliance with multiple requirements.
to give you more than 82% protection against bronchiolitis in your first 90 days of life.
In this sense, Llapur highlighted that the results of the study of a new vaccine against the respiratory syncytial virus that causes bronchiolitis in children have already been seen: “One of the studies that was conducted in Maternity and Mayo Clinic, where women in pregnancy with this immunization, it has been seen that it has a level of protection and efficacy against respiratory diseases due to the syncytial virus of 80 percent up to 3 months of life and about 70 percent at 6 months “, said the Once highlighted against this disease – which has high morbidity and mortality in infants and children under 1 year of age – there is no therapeutic strategy so far beyond an approved antibody for premature infants and which offers oxygen support.
Following this line, the researcher argued that the work is underway in phase 3, of preliminary analyzes and highlighted that, although the study continues, with these we begin to see the effectiveness of the vaccine, which makes it probable that the year thereafter, all related submissions are made for its approval.
Another study also conducted between the public and private health sectors – Avellaneda Hospital and Mayo Clinic – also tests the vaccine against respiratory syncytial virus, but in adults over the age of 60. “This is also a disease that produces symptoms similar to those of influenza or influenza in this population, especially in terms of mortality, morbidity, hospitalizations, and in this case the vaccine was effective close to 85 percent. in the prevention of the disease., therefore it could reduce hospitalizations and severe cases in the elderly, ”he commented.
Llapur also said that the province has also participated – from Niño Jesús hospital and the Mayo Clinic – in studies of a monoclonal antibody for respiratory syncytial virus in children under one year of age, which showed 75% efficacy. : “Today Tucumán, both in the public and private part in terms of research for the prevention of diseases that currently do not have preventive treatments, is working well and results are being produced, for this reason we appreciate the support of the Ministry and the population that participates so that to contribute to science from the province in search of better health for all ”.
For his part, the medical director of the Mayo Clinic, Victor Zimmermann, He said: “It is a pride for Tucumán and for our center to be able to participate together with the Ministry of Public Health through a union between the public and private sectors, in these investigations. We are very proud of the medical staff who are working within these projects with the results that are displayed and we should work even more together, because the patients are the same “, the professional reflected, adding that the work is constantly monitored by them. vaccine manufacturers, which requires compliance with multiple requirements.
